This article is more than 5 years old. Information may no longer be current.

IACTA Pharmaceuticals licenses dry eye technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IACTA Pharmaceuticals Inc. has acquired the North American rights to develop and commercialize NM133, which is designed to help treat dry eye, from its developer, Nanomerics, Ltd.

Nanomerics is a research-stage company with a proprietary Molecular Envelope Technology licensed from University College London that allows a hydrophobic drug to be encapsulated and delivered to the tissues of the eye, the company explained in a press release.

“Nanomerics believes IACTA is the ideal North American licensee for NM133,” Prof. Andreas Schatzlein, CEO of Nanomerics, said in the release. “The need for better medicines remains undiminished, and drugs need to be used to their full potential to deliver patient benefit. “Nanomerics’ Molecular Envelope Technology is engineered at the nanoscale to efficiently deliver drugs for a variety of applications,” he continued. “NM133 is a product in which many of the MET attributes are being exploited to bring tangible benefits to those suffering from dry eye disease.”